Formulation of Solid Lipid Nanoparticles of Cilnidipine for the Treatment of Hypertension
Abstract
Cilinidipine is a fourth generation N and L-type calcium channel antagonists used alone or in combination with another drug to treat hypertension. Cilnidipine is poorly water -soluble, BCS class II drug with 6 to 30 percent oral bioavailability due to first pass metabolism. So to protect the drug from degradation and improve its dissolution, solid lipid nanoparticles were prepared. Glyceryl monostearate was selected as lipid while span 20: tween 20 were selected as surfactant blends. The formulations were evaluated for various parameters, as percent transmittance, drug content, percent encapsulation efficiency; percent drug loading, In vitro drug release and particle size. Optimized formulation was lyophilized using lactose as a cryo-protectant. The lyophilized formulation was evaluated for micromeritic properties, particle size and in vitro dissolution. It was further evaluated for DSC, XRD, and SEM. Percent encapsulation efficiency and percent drug loading of optimized formulation (F3) were 78.66percent and 9.44percent respectively. The particle size of F3 formulation without drug was 204 nm and with the drug was 214 nm. The particle size of the reconstituted SLN was 219 nm. In DSC study, no obvious peaks for cilnidipine were found in the SLN of cilnidipine indicated that the cilnidipine must be present in a molecularly dissolved state in SLN. In X-ray diffractometry absence of peaks representing crystals of cilnidipine in SLN indicated that the drug was in an amorphous or disordered crystalline phase in the lipid matrix. Thus, solid lipid nanoparticle formulation is a promising way to enhance the dissolution rate of cilnidipine.
Keywords: Cilnidipine, Solid Lipid Nanoparticle, Hypertension
Downloads
References
2. Sakaki T, Naruse H, Masai M, Takahashi K, Ohyanagi M, Iwasaki T, Fukuchi M. Cilnidipine as an agent to lower blood pressure without sympathetic nervous activation as demonstrated by iodine-123 metaiodobenzylguanidine imaging in rat hearts. Annals of nuclear medicine. 2003; 17(4):321-6.
3. Chandra KS, Ramesh G. The fourth-generation Calcium channel blocker: cilnidipine. Indian heart journal. 2013; 65(6):691-5.
4. Aritomi S, Koganei H, Wagatsuma H, Mitsui A, Ogawa T, Nitta K, Konda T. The N-type, and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet. Heart and vessels. 2010; 25(6):549-55.
5. Liu XQ, Zhao Y, Li D, Qian ZY, Wang GJ. Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacologica Sinica. 2003; 24(3):263-8.
6. Youssef T, Fadel M, Fahmy R, Kassab K. Evaluation of hypericin-loaded solid lipid nanoparticles: Physicochemical properties, photostability, and phototoxicity. Pharmaceutical development and technology. 2012; 17(2):177-86.
7. Houli L, Zhao X, Ma Y et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. Journal of Controlled Release. 2009; 133:238-44.
8. Xia Q, Hao X, Lu Y, Xu W, Wei H, Ma Q, Gu N. Production of drug-loaded lipid nanoparticles based on phase behaviors of special hot microemulsions. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2008; 313:27-30.
9. Subedi RK, Kang KW, Choi KH. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. European Journal of Pharmaceutical Science.2009; 37:508-513.
10. Luo YF, Chen DW, Ren LX, Zhao XL, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. Journal of controlled release. 2006; 114(1):53-9.
11. Rachmawati H, Rasaputri DH, Tarini S. Preparation and Characterization of Folic Acid-Encapsulated. Journal NANOSAINS & NANOTEKNOLOGI. 2010; 3(2):37-40.
12. Xia Q, Lu YY, Gu N. Preparation of lipid nanoparticles based on phase behaviors of hot microemulsions. In Solid State Phenomena. 2007; 121:847-50.
13. Prabakaran L, Remya B. Formulation and characterization of Domperidone solid lipid nanoparticles in an aqueous system using micro emulsification technique. Journal of Pharmacy Research.2010; 3(12):2944-46
14. Serpe L, Canaparo R, Daperno M et al. Solid lipid Nanoparticles as anti-inflammatory drug delivery system in human inflammatory bowel disease whole- blood model. European J of Pharmaceutical Sci. 2010; 39:428-36
15. Li HL, Zhao XB, Ma YK, Zhai GX, Li LB, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. Journal of Controlled Release. 2009; 133(3):238-44
16. Severino P, Andreani T, Macedo A et al. Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery. Journal of Drug Delivery.2011; 2012:1-6
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Â
.